Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Geoffrey L. Uy, John F. DiPersio, Norbert Vey et al.|Blood|2018Cited by 40